Zydus Lifesciences Limited — Updates, 14-02-2025: Press Release

The USFDA completed a surveillance inspection at Zydus Lifesciences' API manufacturing plant in Ambernath, Maharashtra, with the inspection taking place from February 10 to 14, 2025. Notably, the inspection concluded with no observations, indicating compliance with regulatory standards. This positive outcome reinforces Zydus's operational credibility and may enhance its competitive edge in the pharmaceutical sector. Investors should view this development favorably, as it mitigates potential risks associated with regulatory scrutiny and could support future growth in API production, aligning with the company’s strategic objectives.